

Press release  
22 February 2024

## **Curasight publishes information memorandum in connection with forthcoming rights issue**

**Copenhagen, Denmark, 22 February 2024 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) has prepared and published an information memorandum (the "Information Memorandum") relating to the new issue of shares with preferential rights for the Company's existing shareholders of up to DKK 51.2 million before transaction costs (the "Rights Issue"), which was resolved by the Board of Directors on 13 February 2024. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites ([www.curasight.com](http://www.curasight.com), [www.nordic-issuing.se](http://www.nordic-issuing.se), [www.redeye.se](http://www.redeye.se)).**

### **Summary of the Rights Issue**

- Each existing share in the Company, as of the record date on 22 February 2024, entitles the holder to one (1) subscription right. Seven (7) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of DKK 18 per share.
- The subscription period runs from 23 February 2024, up to and including 7 March 2024.
- The Company's management team, consisting of Ulrich Krasilnikoff (CEO and CFO), Andreas Kjær (CSO/CMO and co-founder) and Hanne Damgaard Jensen (CDO/COO), and members of the Company's Board of Directors, consisting of Per Falholt, Charlotte Vedel, and Kirsten Drejer, have committed to subscribe for shares in the rights issue for a total of approx. DKK 1.7 million, corresponding to 3.4 percent of the rights issue.
- The proceeds are intended to be used to strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, including the preparation, planning and enrolment of the first patients in a therapy phase I/IIa basket trial in various cancer types (brain, neuroendocrine, head and neck, non-small cell lung and pancreatic cancer), as well as to strength Curasight's pipeline through development of new peptide-based radioligand therapies.

### **Information Memorandum**

Full terms and conditions for the Rights Issue as well as other information about the Company and further information about subscription commitments, is included in the Information Memorandum. The Information Memorandum is available on the Company's, Nordic Issuing AB's and Redeye AB's respective websites ([www.curasight.com](http://www.curasight.com), [www.nordic-issuing.se](http://www.nordic-issuing.se), [www.redeye.se](http://www.redeye.se)). Subscription forms will be available on the Company's, Nordic Issuing AB's, and Redeye AB's respective websites.

## Timetable for the Rights Issue

21 February – 5 March 2024	Trading in subscription rights
22 February 2024	Record date for the Rights Issue
22 February 2024	Publication of the Information Memorandum
23 February – 7 March 2024	Subscription period
23 February until the Rights Issue is registered with the Danish Business Authority	Trading in temporary shares
Around 12 March 2024	Estimated publication of the outcome in the Rights Issue

### Advisors

Redeye AB is acting as a financial advisor to Curasight. DLA Piper Denmark Advokatpartnerselskab is acting as the legal adviser of Curasight. VP Euronext Securities A/S is the Company's issuing agent and Nordic Issuing is acting as the settlement agent.

### For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO  
 Phone: +45 22 83 01 60  
 E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.

*This announcement does not constitute and is not a part of an offer to sell securities. Copies of this announcement are not made and may not be distributed, published or sent to the United States, Australia, Hong-Kong, Japan, Canada, Switzerland, Singapore, South Africa or New Zealand or any other jurisdiction where distribution of this press release would be unlawful or require registration or other measures. This announcement is for information purposes only and does not constitute a prospectus or any other offer to sell or a solicitation to offer to acquire any securities in the United States or any other jurisdiction. Securities that may be issued in connection with the transactions referred to in this announcement will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and consequently will not be offered or sold within the United States.*

*This announcement does not constitute a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and the Council (the "Prospectus Regulation"). This press release does not contain and does not constitute an invitation or an offer to acquire, sell, subscribe or otherwise trade in shares, warrants, subscription rights or other securities of Curasight in the United States or elsewhere. The Rights Issue is exclusively targeted at investors in Denmark and is subject to local Danish exemptions for the production and publication of a prospectus. The invitation to affected persons to subscribe for shares in Curasight will only take place through the Information Memorandum that Curasight has published on*



PROVIDING ANSWERS FOR CANCER PATIENTS

*the Company's website. The Information Memorandum contains, among other things, risk factors, certain financial information and information about the Company's management and Board of Directors. This press release has not been approved by any regulatory authority and does not constitute a prospectus. Investors should not subscribe or acquire securities referred to in this press release except on the basis of the information that is be contained in the Information Memorandum that has been published.*

*Topics discussed in this announcement may constitute forward looking statements. Forward looking statements are statements that are not historical facts that can be identified by the use of words such as, "believe", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should" and similar expressions. Forward looking statements in this press release are based on various assumptions, many of which in turn are based on further assumptions. Although CuraSight believes these assumptions were reasonable when made, these assumptions are inherently associated with known and unknown material risks, uncertainties, unforeseen events and other important factors that are difficult or impossible to predict and that are beyond its control. Such risks, uncertainties, unforeseen events and other important factors could cause actual events to differ materiality from the expectations expressed or implied in this announcement by such forward looking statements. Information, opinions and forward looking statements contained in this announcement speak only as at its date, and may be changed without notice.*